Lebanon Industry Brief
SEE OTHER BRANDS

Catch up with industries and services news from Lebanon

Lebanon Industry Brief: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Lebanon Industry Brief.

Press releases published on September 17, 2025

عدد مستخدمي منصة PartyPlatform الإماراتية يصل إلى 10,000 مستخدم، ما يُحدث تحولًا في قطاع تنظيم الفعاليات بالإمارات من خلال سوقٍ أكثر ذكاءً
ECD Automotive Design Corrects CUSIP Number
GoldHaven Arranges Non-Brokered Private Placement
Blue Gold Limited Signs Purchase Agreement for Gold & Copper Mining Lease, Marking First Step in Broader Planned M&A Growth Strategy
Woodward Announces Declaration of Dividend
Lithium Chile Announces Life Offering of Up to $5,000,000
Kirby McInerney LLP Reminds Semler Scientific, Inc. Investors of Class Action Filing and Encourages Investors to Contact the Firm
RCI Hospitality Holdings, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (RICK)
Accounts Payable Services | Save 40% with Rely Services
Xcite Resources Announces Concurrent Brokered Life Offering & Flow-Through Shares Private Placement Alongside Amending Agreements Respecting Athabasca Uranium Portfolio
Fanspicy Announces Expanded Payment Solutions for Creators
HII Hosts Marine Corps Commandant Gen. Eric Smith at Ingalls Shipbuilding
CEMATRIX to Host Investor Webcast on September 25, 2025
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
Atico Signs the Investment Protection Agreement with Government of Ecuador for its La Plata Project
InterDigital Declares Increase in Quarterly Cash Dividend
MDWerks’ Two Trees Beverage Subsidiary Announces New Collaboration with French Broad Chocolate
Toll Brothers Announces Cash Dividend
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions